Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41391-025-00947-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CT-based radiomics-deep learning model predicts occult lymph node metastasis in early-stage lung adenocarcinoma patients: A multicenter study.
Chin J Cancer Res
January 2025
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, China.
Objective: The neglect of occult lymph nodes metastasis (OLNM) is one of the pivotal causes of early non-small cell lung cancer (NSCLC) recurrence after local treatments such as stereotactic body radiotherapy (SBRT) or surgery. This study aimed to develop and validate a computed tomography (CT)-based radiomics and deep learning (DL) fusion model for predicting non-invasive OLNM.
Methods: Patients with radiologically node-negative lung adenocarcinoma from two centers were retrospectively analyzed.
New index for quantitative comparison of dose distributions in radiotherapy.
Med Phys
March 2025
Florida Cancer Specialists & Research Institute, Hudson, Florida, USA.
Background: Delivery of intensity modulated radiotherapy (IMRT) requires patient specific quality assurance (QA) tests. These tests normally include a two-fold comparison of dose distributions: (a) comparison of planned dose created in the employed treatment planning system (TPS) and dose computed by using third-party software; (b) comparison of planned (predicted) and delivered doses.
Purpose: We describe a new approach to compare dose distributions in radiotherapy.
Harnessing Baseline Radiomic Features in Early-Stage NSCLC: What Role in Clinical Outcome Modeling for SBRT Candidates?
Cancers (Basel)
March 2025
Division of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
An Early-Stage Non-Small Cell Lung Cancer (ES-NSCLC) patient candidate for stereotactic body radiotherapy (SBRT) may start their treatment without a histopathological assessment, due to relevant comorbidities. The aim of this study is twofold: (i) build prognostic models to test the association between CT-derived radiomic features (RFs) and the outcomes of interest (overall survival (OS), progression-free survival (PFS) and loco-regional progression-free survival (LRPFS)); (ii) quantify whether the combination of clinical and radiomic descriptors yields better prediction than clinical descriptors alone in prognostic modeling for ES-NSCLC patients treated with SBRT. Simulation CT scans of ES-NSCLC patients treated with curative-intent SBRT at the European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy between 2013 and 2023 were retrospectively retrieved.
View Article and Find Full Text PDFStereotactic body radiotherapy combined with immunotherapy or targeted therapy: a screenshot from Italy on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO).
Radiol Med
March 2025
Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Aim: Despite the widespread use of immunotherapy (IO) and targeted therapy (TT) in clinical practice, data on toxicity in combination with SBRT are lacking, largely based on retrospective studies and case reports. The present survey, conducted within the AIRO Oligometastatic Study Group, was developed for radiation oncologists to investigate the current clinical practice in Italy regarding hypofractionated SBRT (defined as a dose/fraction ≥ 5 Gy) in cancer patients using IO and TT.
Methods: The online survey, composed of 19 questions, was developed using the cloud-based platform SurveyMonkey® and was sent to all registered AIRO members using the association's mailing list and was administered online and in anonymous form.
AAPM-RSS Medical Physics Practice Guideline 9.b: SRS-SBRT.
J Appl Clin Med Phys
March 2025
Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
The purpose of this Medical Physics Practice Guideline (MPPG) is to describe the minimum level of medical physics support deemed prudent for the practice of linear-accelerator, photon-based (linac) stereotactic radiosurgery (SRS), and stereotactic body radiation therapy (SBRT) services. This report is an update of MPPG 9.a published in 2017.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!